PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35237165-12	2022	Thus, CSAD, as the possible new therapeutic target of EDA, was selected and validated by Western blot and immunofluorescence.	Edaravone	54-57	cysteine sulfinic acid decarboxylase	Mus musculus	6-10	
35237165-13	2022	Together, this study provided the metabolite signatures and identified CSAD as an unrecognized therapeutic intervention for EDA in the treatment of ischemic stroke via inhibiting brain endothelial cell apoptosis.	Edaravone	124-127	cysteine sulfinic acid decarboxylase	Mus musculus	71-75